Mehmet KARADAĞ, R.Oktay GÖZÜ, Funda COŞKUN, Dursun Ali SAĞLAM, Arzu Yılmaztepe ORAL, Ahmet URSAVAŞ

Akciğer kanserli olgularda serum “vascular endothelial growth factor (VEGF)” düzeylerinin metastazlar ve diğer tümör belirteçleri ile ilişkisinin incelenmesi

“Vascular endothelial growth factor (VEGF)” anjiyogenezin potent bir mediatörüdür. Yüksek VEGF değerleri ileri evre akciğer kanseri ve kötü prognoz işareti olabilir. Biz akciğer kanserinde tümör evresi ile serum VEGF ilişkisini ve ayrıca serum VEGF ile diğer bazı tümör belirteçlerinin korelasyonunu araştırdık. Yeni akciğer kanseri tanısı konulan 40 (31 küçük hücreli dışı, 9 küçük hücreli) olgu ile 25 sağlıklı kontrol çalışmaya dahil edildi. Serum VEGF düzeyi akciğer kanserli hastalarda (345.16 ± 159.36 pg/mL) kontrol grubuna (230.36 ± 47.87 pg/mL) göre anlamlı düzeyde yüksek saptandı (p< 0.001). ROC analizinde serum VEGF 249.8 pg/mL değerinin (eğri altındaki alan 0.727 ve p< 0.05), akciğer kanserini göstermede sensitivitesi %70, spesifisitesi %76 olarak saptandı. Serum VEGF ile yaş, cinsiyet, tümörün histolojik tipi, tümör evresi, uzak metastaz varlığı ve metastaz yeri arasında ilişki yoktu. Ayrıca, diğer tümör belirteçleri (NSE, CYFRA 21-1, CEA, CA125, LDH) ile serum VEGF düzeyi arasında korelasyon saptanmadı.

The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer

Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis. Increased expression of VEGF may be associated with advanced stage and poor prognosis in patients with lung cancer. We investigated the relationship between serum VEGF level and lung cancer stage. We also studied the correlation between serum VEGF level and some other tumor markers. Forty newly diagnosed lung cancer (31 non-small cell, 9 small cell) patients and 25 age-matched controls were enrolled in this study. Serum VEGF levels of lung cancer group (345.16 ± 159.36 pg/mL) were significantly higher than that of the control group (230.36 ± 47.87 pg/mL) (p< 0.001). The area under the ROC curve was 0.727 (p< 0.05) for serum VEGF threshold of 249.8 pg/mL predictive sensitivity and specificity, for lung cancer were respectively 70.0% and 76.0%. There were no significant relationship between serum VEGF level and age, gender, histologic type, lung cancer stage, distant metastases and site of metastases. In addition, there were no correlation between serum VEGF level and other tumor markers (NSE, CYFRA 21-1, CEA, CA125, LDH)

PDF

___

1. Bozkurt B, Selçek T, Fırat P ve ark. 1972-2002 döneminde Hacettepe Üniversitesi Tıp Fakültesi Hastanesi’nde akciğer kanseri tanısı konulan hastaların histolojik ve epidemiyolojik değerlendirmesi. Toraks Dergisi 2004; 5:148-53.
2. Köktürk N, Kırışoğlu CE, Öztürk C. Akciğer kanseri moleküler biyolojisi. Solunum 2003; 5: 127-38.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
4. Kırışoğlu CE, Öztürk C, Köktürk N. Küçük hücreli dışı akciğer kanserinde epidermal büyüme faktörü reseptörü ve inhibitörlerinin yeri. Solunum 2003; 5: 146-52.
5. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
6. Yano S, Nishioka Y, Goto H, Sone S. Moleculer mechanisms of angiogenesis in non-small lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94: 479-85.
7. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3): 4-10. 2005; 21 Epub
8. Mountain CF. Revision in the ienternational system for staging lung cancer. Chest 1997; 111: 1710-7.
9. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
10. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growt factor in human colon cancer: Biology and therapeutic implications. The Oncologyst 2000; 5(Suppl): 11-5.
11. Tae K, El-Naggar AK, Yoo E, et al. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clinical Cancer Research 2000; 6: 2821-8.
12. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002; 55: 348-59.
13. Bellamy WT, Richter L, Frutiğer Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research 1999;59: 728-33.
14. Kishiro I, Kato S, Fuse D, et al. Clinical significance of vascular endothelial growth factor in patients with, primary lung cancer. Respirology 2000; 7: 93-8.
15. Baillie R, Carlile J, Pendloton N, Schor AM. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 2001; 54: 116-20.
16. Ohta Y, Ohta N, Tamura M, et al. Vascular endothelial growth factor expression in airways of patients with lung cancer. Chest 2002; 121: 1624-7.
17. Kaya A, Ciledag A, Eris Gulbay B, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell cancer patients. Respiratory Medicine 2004; 98: 632-6.
18. Morragi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clinical Cancer Research 2000; 6: 4739-44.
19. Nakashima T, Huang CI, Liu D, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit 2004; 10: 157-65.
20. Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in non-small cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-14.
21. Matsuyama W, Hashuguchi T, Mizoguchi A, et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000; 118:948-51.
22. Laack E, Köhler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002; 13: 1550-7.
23. Demirkazık A, Akbulut H, Ulger AF, et al. Serum vascular endothelial growth factor levels in patients with nonsmall cell lung cancer. Ann Saudi Med 2004; 24: 473-5.
24. Fukasawa T, Fujisawa T, Yamaguchi Y, et al. Clinical evaluation of serum NSE and CEA in primary lung cancer patients. Gan To Kagaku Ryoho 1986; 13: 1862-7.
25. Hasegawa Y, Takanashi S, Okudera T, et al. Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanise patients. Internal Medicine 2005; 44: 26-34.
26. Mall JW, Schwenk W, Philipp AW, et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-spesific enolase or lactate dehydrogenase. Respirology 2002; 7: 99-102.